Trade name for levalbuterol HCI, which is a sub-component of racemic albuterol/ salbutamol. The stated benefit of bronchodilation with Xopenex is reduced incidence of stimulative side-effects such as heart palpitations, tremors and nervousness. It is currently available in the US in nebulizer solution and is not yet FDA-approved for use in children under age 12, which is not to say that it is unsafe for use in children, just that anough testing has not yet been completed to justify the FDA's approval.